Canine Osteosarcoma Clinical Trial

Enrollment in the trial is now closed. Results will be available in 2022.

Trial Overview

ELIAS Animal Health recently conducted a clinical trial to evaluate its ELIAS cancer immunotherapy (ECI®)—a vaccine-enhanced adoptive cell therapy—combined with surgery as a treatment for canine osteosarcoma. The study enrolled 102 dogs at 10 study sites across the country.

ELIAS has developed a unique immunotherapy treatment protocol which may permit the dog’s immune system to attack its own cancer cells. ECI has demonstrated effectiveness in clinical trials in both canines and humans, while avoiding or minimizing the need for chemotherapy or radiation treatment.

  – Trial enrollment was required prior to amputation (affected limb must be intact)
– Treatment included either ECI immunotherapy or carboplatin chemotherapy
– Patients completed a 7-11 week treatment regimen and returned for quarterly follow-up visits throughout the 18-month trial

To learn more about this therapy and to see if your dog or canine patient may be a good candidate for treatment, please schedule a visit with a participating hospital near you.

Cancer Immunotherapy. Personalized.

Our approach is profoundly simple: Every canine patient is unique. Every cancer is unique. To ultimately win against this devastating killer, cancer therapy itself must also be unique. ELIAS Cancer Immunotherapy (ECI®), our Autologous Prescription Product, harnesses the power of the dog’s own immune system to eliminate the cancer. Find out if a dog meets our criteria.

Killer T cells. Activated.

The complexity of cancer itself makes the development and delivery of effective treatments a steep challenge. Research has shown that ex vivo activated T cells have the capability to effectively kill cancer cells, including cancer stem cells. The ECI® treatment utilizes adoptive cell therapy to deliver an army of activated T cells.

Two Methods. Combined.

ELIAS Animal Health has developed a unique treatment protocol that vaccinates the dog with its own cancer cells to produce an immune response. Personalized T cells are then safely obtained from the patient through apheresis and activated to produce a large population of killer T cells that are reinfused into the patient to attack the cancer.

Benefits. Expanded.

ELIAS’ cancer immunotherapy is a platform technology that has demonstrated effectiveness in clinical trials in both canines and humans, while avoiding or minimizing the need for chemotherapy or radiation treatment. ELIAS is taking cancer treatment to new heights.

“I really think that there is strong evidence that the ELIAS procedure benefited these dogs, substantially and on average, based on that median survival. I will also point out that every single piece of the ELIAS immunotherapy process is extremely well supported in the scientific literature across multiple species.”

Jeffrey Bryan, DVM, DAVCIM (Oncology)

“The T cell expansion is a huge component that, to my knowledge, none of the other autologous products are even trying to replicate.”

Zachary Wright, DVM, DACVIM (Oncology)

“And as one of the persons that has been involved in them, there’s going to be a never-ending irreversible limitation of what autologous vaccine alone can do, which is why I’m attracted to the ECI product because of the activated T cell component. I don’t think that any of these products or autologous vaccines that are out there today are that much different or are going to offer that much significant difference. Whereas I think ECI has some clear improvements and should result in better results and better outcomes.”

K. Ann Jeglum, VMD, DACVIM (Oncology)